2seventy bio, Inc.
TSVT
$12.15
$0.070.58%
| Weiss Ratings | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.67% | |||
| 30-Day Total Return | 41.94% | |||
| 60-Day Total Return | 13.45% | |||
| 90-Day Total Return | -4.63% | |||
| Year to Date Total Return | 30.79% | |||
| 1-Year Total Return | 4.11% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -35.65% | |||
| 52-Week Low % Change | 47.27% | |||
| Price | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $18.88 | |||
| 52-Week Low Price | $8.25 | |||
| 52-Week Low Price (Date) | Apr 24, 2023 | |||
| 52-Week High Price (Date) | Aug 10, 2022 | |||
| Valuation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $609.92M | |||
| Enterprise Value | 535.51M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.46 | |||
| Earnings Per Share Growth | -54.22% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.24 | |||
| Price/Book (Q) | 1.52 | |||
| Enterprise Value/Revenue (TTM) | 4.29 | |||
| Price | $12.15 | |||
| Enterprise Value/EBITDA (TTM) | -2.51 | |||
| Enterprise Value/EBIT | -2.39 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.468M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 339 499 9300 | |||
| Address | 60 Binney Street Cambridge, MA 02142 | |||
| Website | www.2seventybio.com | |||
| Country | United States | |||
| Year Founded | 2021 | |||
| Profitability | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -179.65% | |||
| Profit Margin | -172.80% | |||
| Management Effectiveness | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -17.56% | |||
| Return on Equity | -- | |||
| Income Statement | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $124.69M | |||
| Total Revenue (TTM) | $124.69M | |||
| Revenue Per Share | $2.87 | |||
| Gross Profit (TTM) | -$153.03M | |||
| EBITDA (TTM) | -$213.75M | |||
| EBIT (TTM) | -$224.01M | |||
| Net Income (TTM) | -$215.46M | |||
| Net Income Avl. to Common (TTM) | -$215.46M | |||
| Total Revenue Growth (Q YOY) | 393.78% | |||
| Earnings Growth (Q YOY) | 45.14% | |||
| EPS Diluted (TTM) | -$5.46 | |||
| EPS Diluted Growth (Q YOY) | 66.24% | |||
| Balance Sheet | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $339.93M | |||
| Cash Per Share (Q) | $7.82 | |||
| Total Current Assets (Q) | $389.82M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $401.32M | |||
| Current Ratio (Q) | 5.067 | |||
| Book Value Per Share (Q) | $8.00 | |||
| Total Assets (Q) | $742.44M | |||
| Total Current Liabilities (Q) | $76.93M | |||
| Total Debt (Q) | $266.95M | |||
| Total Liabilities (Q) | $341.11M | |||
| Total Common Equity (Q) | $401.32M | |||
| Cash Flow | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | $11.75M | |||
| Cash from Financing (TTM) | $123.21M | |||
| Net Change in Cash (TTM) | -$77.20M | |||
| Levered Free Cash Flow (TTM) | -$159.87M | |||
| Cash from Operations (TTM) | -$212.16M | |||
